![nhs evidence eye](https://www.nationalelfservice.net/cms/wp-content/uploads/2011/03/nhs-evidence-eye-150x150.jpg)
The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease has resulted in a change in the guidance. Specifically: donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer’s disease, and memantine is now recommended as an option for managing moderate Alzheimer’s [read the full story…]